10-Q · May 14, 2026
SRx Health Solutions, Inc. reported total net sales of $3.4 million for Q4 2026, reflecting an operational shift away from specialty healthcare to the Consumer Products segment focused on pet nutrition. The company is…
Earnings analysis · 10-Q
SRXH earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The filing reports $3.392 million of revenue and $(0.36) EPS, but the provided extract does not include prior-period or prior-year financial statements, margins, balance-sheet data, cash flow, or segment results. No…
Read full summary
The filing reports $3.392 million of revenue and $(0.36) EPS, but the provided extract does not include prior-period or prior-year financial statements, margins, balance-sheet data, cash flow, or segment results. No quantitative outlook or guidance was provided. Management reported effective disclosure controls as of June 30, 2026, while risk factors were unchanged from the December 5, 2025 Annual Report.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.36
What stood out
-
Quarterly revenue and EPS reported
Reported revenue was $3.392 million and EPS was $(0.36) for the quarter. Prior-period and prior-year comparatives were not included in the provided filing extract, so trend magnitude cannot be calculated.
-
Disclosure controls assessed effective
Management stated that disclosure controls and procedures were effective as of June 30, 2026, following evaluation by the CEO and CFO.
-
No material control changes identified
The company stated that no changes during the quarter ended June 30, 2026 materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
Risk-factor disclosure unchanged
The filing states there have been no material changes from the risk factors in the Annual Report filed on December 5, 2025. Accordingly, the current report does not provide an updated ranking or quantification of key business risks.
Management's outlook
The provided 10-Q text contains no quantitative revenue, EPS, margin, cash-flow, or capital-spending outlook. No comparison with prior guidance is available.
Earlier filings 4
10-Q · February 13, 2026
SRx reported continuing-operations net sales of $2,807,000 for the quarter (previous-year quarter: $0), generating gross profit of $1,054,000 (~37.6% gross margin) but a continuing-operations loss of $8,614,000 (loss…
10-K · December 5, 2025
SRx completed a strategic reset during FY2025: the company discontinued its capital-intensive Canadian specialty healthcare operations (SRx Canada) and is now a much smaller, consumer-products-only business focused on…
10-Q · September 30, 2025
SRx Health Solutions reported a sharp deterioration in operating results for the quarter ended June 30, 2025: revenue fell to $11.447M from $42.670M year-over-year, driving a wider operating loss and a deeper EPS loss.…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.